Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis
Authors' conclusion
Our results suggest routine screening for MASLD in obesity clinics is not cost-effective with resmetirom as the available treatment. A prescreening with FIB-4 before TE did not increase economic efficiency.
Study context
- Population
- Persons with obesity; MASLD-related advanced hepatic fibrosis (fibrosis stage > 2); detected MASLD treated with resmetirom
- Comparison
- Transient elastography (TE) vs FIB-4 followed by TE vs no screening for MASLD-related advanced fibrosis
- Outcome
- Cost-effectiveness (ICER) of screening strategies
Methodological detailsdecision-analytic model, Markov transition model, multivariate simulations
- Decision-analytic model
- Markov transition model
- Multivariate simulations
Main finding
As reported in the abstract
ICER · 10-year screening interval
Incremental cost-effectiveness ratio (ICER)
$234,781
95% CI $232,581, $235,608
TE vs No screening · 10-year interval
ICER
$234,673
95% CI $234,033, $235,072
TE vs FIB-4+TE
Further findings
Multivariate simulations
- No screening most likely cost-effective for willingness-to-pay for QALY below approximately $250,000
Original publication
Screening for MASLD and Advanced Fibrosis Among Patients With Obesity: A Cost‐Effectiveness Analysis. Obesity (Silver Spring). Published 13 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →